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Abstract
Background: Nursing home patients have complex mental and physical health problems, disabilities and social
needs, combined with widespread prescription of psychotropic drugs. Preservation of their quality of life is an
important goal. This can only be achieved within nursing homes that offer competent clinical conditions of
treatment and care. COmmunication, Systematic assessment and treatment of pain, Medication review,
Occupational therapy, Safety (COSMOS) is an effectiveness-implementation hybrid trial that combines and
implements organization of activities evidence-based interventions to improve staff competence and thereby the
patients’ quality of life, mental health and safety. The aim of this paper is to describe the development, content and
implementation process of the COSMOS trial.
Methods/Design: COSMOS includes a 2-month pilot study with 128 participants distributed among nine Norwegian
nursing homes, and a 4-month multicenter, cluster randomized effectiveness-implementation clinical hybrid trial with
follow-up at month 9, including 571 patients from 67 nursing home units (one unit defined as one cluster). Clusters are
randomized to COSMOS intervention or current best practice (control group). The intervention group will receive a
2-day education program including written guidelines, repeated theoretical and practical training (credited education
of caregivers, physicians and nursing home managers), case discussions and role play. The 1-day midway evaluation,
information and interviews of nursing staff and a telephone hotline all support the implementation process. Outcome
measures include quality of life in late-stage dementia, neuropsychiatric symptoms, activities of daily living, pain,
depression, sleep, medication, cost-utility analysis, hospital admission and mortality.
Discussion: Despite complex medical and psychosocial challenges, nursing home patients are often treated by
staff possessing low level skills, lacking education and in facilities with a high staff turnover. Implementation of a
research-based multicomponent intervention may improve staff’s knowledge and competence and consequently the
quality of life of nursing home patients in general and people with dementia in particular.
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Background
The rapidly growing population of elderly persons in
Europe is subject to frequent and numerous comorbi-
dities, impaired organ function and problems linked to
access to care and skilled treatment [1]. Dementia is in-
creasingly common in the ageing population, with ap-
proximately 35 million affected people worldwide and 10
million in Europe [2, 3]. This number is expected to
double within the next three decades, thus posing a con-
siderable challenge for the healthcare system and society.
Whereas one in four Americans die in a nursing home
(NH) every year [4], almost half of the Norwegian citi-
zens die in a NH [5]. In Norway, it has been estimated
that 70,000 people have dementia, 34,000 of whom live
in a NH [6] and have a stay of about 24 months mean
length before death. More than 80 % of those living in a
NH have dementia [7], often combined with stroke,
heart failure or cancer. They have distressing mental
health problems, such as agitation and depression [8],
physical disabilities and unmet social requirements, and
they are often in pain [9, 10]. The prescription of
medication is high, including potentially harmful psy-
chotropic drugs [11]. In addition, these people are in
significant need of advance care planning [12] and
meaningful activities [13].
In order to meet these challenges, the Norwegian
Government encourages the municipalities to develop
services and staff competence to improve mental health
and quality of life (QoL) in NH patients and people
with dementia as set out in the Coordination Reform
(Norwegian Government report: 47 2008-2009). Objec-
tives are in line with the National Research Program on
Health, Care and Welfare Services 2015–2024 support-
ing research to develop and evaluate effective and com-
plex interventions in large-scale research projects with
a multidisciplinary approach, and including elderly NH
patients with chronic diseases.
Responsibility for care and treatment of older people
depends on the commitment and capability of the pri-
mary healthcare system. However, despite these complex
tasks, NH patients are often treated by unqualified staff
who lack education, knowledge and basic skills in terms
of understanding patient behaviour, and who have insuf-
ficient expertise in how to treat and give proper care to
persons with dementia [6].
Rationale for the present trial
The number of cluster randomized clinical trials (RCT)
including NH patients with and without dementia that
are designed to investigate the efficacy of competence
improvement programs combined with clinical treat-
ment methods has increased in the last decade. For in-
stance, implementation of introductory communication
in the form of advance care planning (ACP) in NHs
resulted in fewer deaths in hospitals and reduced re-
source use [12], better end-of-life care and pertinent eth-
ical discussions, and satisfied relatives and staff [14].
Another example is the stepwise protocol of treating
pain (SPTP) in people with dementia which succeeded
in the reduction of agitation [15], mood syndrome [16]
and pain [10]. Previously, systematic medication reviews,
including staff education, workshops and face-to-face
interaction between the prescribing physician and an
expert-group, have been found to reduce unnecessary
and harmful drug prescription [17]. Finally, a current
systematic review by Testad et al. (2014) highlighted the
benefit of systematic organization of activities [13] and
described improvements in neuropsychiatric symptoms
for reminiscence therapy [18–20], personalized pleasant
activities [21–23] and person-centered care [24–26].
It is of key importance that these single interventions
improved either behaviour such as agitation and aggres-
sion, reduced use of the total medication and antipsy-
chotics, or hospital admissions. However, none of the
single interventions resulted in an improvement of the
QoL in NH patients. In addition, the evaluation of the
actual implementation process of the interventions has
largely been neglected.
The COSMOS intervention
It is a basic requirement of human rights that a person is
informed about her or his disease and be enabled to con-
sider future plans and decisions [27–29], be out of pain
[15, 30, 31], receive proper medical treatment [32, 33] and
be involved in meaningful activities [13, 21, 34]. The
COSMOS intervention is based upon results of earlier
RCTs and will combine, implement and test the most ef-
fective components for developing an optimal multicom-
ponent and systematic intervention by (Fig. 1):
– COmmunication
– Systematic assessment and treatment of pain
– Medication review
– Organization of activities and
– Safety
Changing clinical practice requires attention to multiple
factors that influence individuals’ or groups’ willingness
and ability to incorporate new knowledge of care [35].
Whereas education of clinicians alone is reported to be in-
effective in changing care practices, complex multicompo-
nent interventions that incorporate clinicians’ education
have been reported to be successful [36]. The COSMOS
trial is an evidence-based effectiveness-implementation
hybrid trial funded by the Norwegian Research Council.
We intend to use mixed qualitative and quantitative
methods to test the effectiveness of the multifaceted inter-
vention and to develop and test the implementation
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strategy for NH staff. In this paper, we describe the
development of the COSMOS intervention; development
of the education program; education of the COSMOS
implementers (COSMOS ambassadors); implementation
process in intervention NHs; support procedures, and
statistical analyses.
The COSMOS program is based on evidence from the
literature, and scientific and clinical experiences of the
research group including research projects with cross-
sectional, trajectory and RCT design, and a review of the
literature. The COSMOS researchers are involved in
education programs and teaching activities for health-
care professionals, people with dementia and relatives
both at a national and international level. The combin-
ation of evidence for best practice and expertise related
to education and training has been used to build up a
systematic intervention which transfers evidence-based
knowledge into an understandable everyday quality im-
provement intervention.
Implementation strategies
One of the greatest challenges facing the global health
community is to take proven interventions and implement
them into the real world. The term “to implement” means
“to carry out into effect”. Implementation research is
defined as the related scientific investigation concerning
the implementation process and the act of carrying an
intention into effect in a real-world scenario [37, 38]. For
the COSMOS trial, this means that research-based know-
ledge is to be transferred into practice with the selection
of NH patients who mirror a broad variety of current
quality in care and treatment offered in NHs.
A crucial aspect when assessing the effect of a com-
plex intervention study is whether or not the interven-
tion was implemented at all. Even when an intervention
is superbly designed, real-world contextual factors may
prevent the intervention from being realized as intended
in a complex adaptive system [39, 40]. The intervention
may not be completed, or it may be completed differ-
ently than originally intended, not systematic or plainly
wrong. In other words, it is necessary not only to evalu-
ate the intervention effect but also to evaluate imple-
mentation fidelity and sustainability [40].
Aims of the COSMOS trial
The primary objective with the COSMOS trial is to im-
prove the QoL in NH patients by enhanced communica-
tion in form of ACP, proactive assessment and treatment
of pain, discontinuation of unnecessary medication and
organization of activities. The secondary objective is to
determine the effectiveness by core outcome measure-
ments of mental and physical health, pain, sleep, safety,
total drug use, hospital admission and cost-effectiveness.
We also investigate how successful the implementation
process was and staff satisfaction.
Methods and design
This is a 4-month multicenter, cluster randomized and
controlled effectiveness-implementation hybrid trial with
follow-up at month 9, involving 571 participants from
67 NH units in Norway (Flow chart in Fig. 2). The
mixed method design comprises the quantitative assess-
ment with validated outcome measures and qualitative
research of the intervention strategy by implementation
indicators [40]. Very few studies have focused on these
critical issues, hence the key attention of this project is
to explore how the combination of an educational pro-
gram for carers and research-based practice and compe-
tence may improve the QoL for NH patients. Until now,
the efforts to improve standard of care in NHs have re-
sulted in many “stints”; that is, most NHs may have had
a campaign focusing on one of the single interventions.
However, if a NH, for instance, offers optimal assess-
ment and treatment of pain, this does not automatically
mean that patients are also provided with meaningful
activities.
Settings and target population
Urban and rural NHs in Southern Norway will be in-
cluded. The mix between urban/rural, big/small munici-
palities from different areas of Norway, extending over
700 kilometers apart, ensures a representative NH po-
pulation. Systematic selection of the clusters will be
achieved through established networks and information
to related municipalities and NH managers. We strived
Fig. 1 COSMOS components
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to ensure collaboration from the top healthcare leaders
of each municipality.
Inclusion criteria: NH patients with and without de-
mentia, ≥65 years old, from 67 clusters, will be recruited.
Diagnoses are based on patient’s medical records, med-
ical examination and routine laboratory tests in the NH.
The patients’ cognitive function is assessed by Mini-
Mental State Examination (MMSE) [41] and Functional
Assessment Staging (FAST) [42].
Exclusion criteria: Dying patients (life expectancy ≤6
months) or patients with diagnoses of schizophrenia will
not be included.
Research questions and study hypotheses in order to
meet the aims of the study
1. To what extent will the implementation of ACP
improve the decision processes and interactions
Fig. 2 Flow chart of the COSMOS trial
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between patients, staff and family and reduce
hospital admissions and costs? We hypothesize
that a systematic communication approach will
empower patients and families to make preferred
choices, be more independent and become better
able to understand the complexity of current
diagnoses, care and treatment.
2. To what extent will previously unidentified pain
be uncovered when the use of MOBID-2 is
implemented? In patients with untreated pain,
to what extent will a stepwise protocol of treating
pain, show benefit on self-reported or proxy-rater
assessed pain by MOBID-2 Pain Scale? We
hypothesize that education and written material
will result in improvements in pain assessment
which will in turn result in excellent pain
treatment and improved QoL.
3. In patients with polypharmacy (≥4 drugs), to
what extent will the systematic protocol of
medication review based on face-to-face discussion
between the responsible physician, NH staff and
research team, following START and STOPP
criteria [43] show benefits in terms of total
medication use, use of psychotropic drugs and
costs [44]. We hypothesize that a systematic
medication review will reduce unnecessary
medication and related costs, thereby improving
the resources available.
4. To what extent will a standardized and
individual plan for activities increase activity
time? We hypothesize that an individual plan for
activities will improve the daytime activity
provision to patients through regular follow-up
and inclusion of relatives and volunteers.
Cluster randomized effectiveness-implementation hybrid
trial
Whereas pragmatic trials conduct a fixed intervention
and do not try to control or ensure the delivery of
services to meet realistic standards in normal practice
settings, effectiveness-implementation hybrid trials also
intervene and/or observe the implementation process as
it actually occurs [37, 45]. Thereby, effectiveness-
implementation hybrid designs are intended to assess
the effectiveness of both an intervention and an im-
plementation strategy. In this context, the expression
“hybrid” signalizes a mixed method study design to
cover the whole process of implementation and assess-
ment of the intervention. Studies include elements of an
effectiveness design (e.g. randomization to intervention
and control group) and investigate, additionally, the
implementation strategy by implementation outcome
variables [45].
Cluster design and blinding
According to the research design, patients, units or even
NHs are cluster randomized to care as usual or treat-
ment. In a hybrid trial design, the implementation strat-
egies, education and follow-up may be optimized during
the process, for the purpose of gaining new understand-
ing and insight. Because of this, the participants, patients
and/or staff related to the clusters cannot be completely
blinded regarding the group allocation. Meanwhile, the
cluster randomized design is the most suitable design for
implementation research, as it reduces the contamination
between the intervention and control groups [46]. Fur-
thermore, the cluster design takes into account the fact
that the participants live together in the NH clusters.
Randomization
Using SPSS, each single NH unit is randomized to inter-
vention or control condition per participating municipal-
ity and matched by urban and rural, prosperous and less
well-to-do status and organizational conditions.
Control condition
The control group will receive care as usual, during the
trial and follow-up period. NHs in the control group have
to show a satisfactory standard of care. This standard will
be verified by the COSMOS team during the data collec-
tion. In addition, the control group will be monitored by
monthly telephone contact. The control group may also
derive a considerable learning effect. Before randomization,
representatives from each NH receive information about
the aim and content of COSMOS, because they have to de-
cide whether they are interested in participating or not.
When NHs are then randomized for control, responsible
staff members receive information on dementia diagnoses,
neuropsychiatric symptoms and pain assessment in people
with dementia as part of the data collection, and they will
be trained in the use of primary/secondary outcome mea-
sures. To motivate control NHs to continue participating,
they will receive the COSMOS intervention after the last
data collection at month 9 by a waiting-list-strategy [47]
supported by a “supervisor” recruited from a NH who has
already received the intervention.
Development of the COSMOS education program
The study intervention will be delivered by the
COSMOS education program and guidelines describing
the COSMOS components: COmmunication, Systematic
assessment and treatment of pain, Medication review,
Organization of activities, and Safety (Figs. 3, 4 and
Appendix). Standardized written material (guidelines, pa-
tient logs, power point, handouts, flash cards, flyer, poster
and entrance placard) that describe the evidence base
background and content of COSMOS is prerequisite for
training. The material has been adapted to language and
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Fig. 3 Detailed overview of the multicomponent COSMOS intervention, education program and outcome measures
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staff competence and reviewed taking into account mental
health and care needs of the patients. After the pilot study,
adaptions are made for the power point presentation, time
use and enhanced feedback system, whereas the content
of the intervention is changed only marginally. For further
follow-up, the standardized and pilot-tested 2-day teaching
program (Appendix) will transfer COSMOS components
(Fig. 3) to the implementers (COSMOS ambassadors), by
a senior researcher (BSH) and postdoctoral research fellow
(EF). Selected NH staff, NH physicians and managers are
invited; at least two colleagues from included units must
participate.
Education of the COSMOS ambassadors
The intervention will be delivered by implementers
called “COSMOS ambassadors”. The COSMOS ambas-
sadors are staff from the intervention NHs. We invite all
physicians, nurses and licensed practical nurses to the
education, but require a minimum of two nurses from
each NH unit in the intervention group to participate.
The COSMOS ambassadors usually registered and li-
censed practical nurses have hands-on experience with
NH patients in their daily work. Ambassadors participate
in the 2-day education (about 2.5 h per COSMOS com-
ponent, role play, patient-centered discussion and feed-
back) following the COSMOS program (Fig. 3 and
Appendix) and receive supervision from the research
team using the COSMOS patient logs and written
COSMOS guidelines. NH managers provide a written
agreement for participation and confirm that staff will
not switch between care units. Given the complexity and
multi-faced nature of the intervention, as well as the
heterogeneous “real-world” population, some variability
in the implementation of the interventions is to be
expected.
Implementation in NHs
After finalizing the COSMOS education program, the
intervention (Figs. 3 and 4) will be delivered by the
ambassadors at each NH unit with a weekly focus; “red
week” for communication, “blue” for systematic assess-
ment and treatment of pain, “yellow” for medication re-
view and “green” for organization of activities. Education
will be offered during lunch and/or report for about
20 min, if possible, several times a week to enable all
staff members to participate. The ambassadors will use
written material and power point presentation to inform
and educate their colleagues. By this, each COSMOS
component will ideally be repeated every month between
baseline and month 4 data collections. To ensure medi-
cation review, two COSMOS researchers (BSH and CG)
sought out the NH physicians and responsible nurses to
perform a collegial face-to-face systematic medication
review. The support by regular telephone contact every
second week, a telephone/email hotline (Monday to
Friday 08:00–16:00) gives NH staff assistance when they
Fig. 4 COSMOS protocol development and implementation strategy
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have concrete questions related to data collection or in-
ternal education. A half day, midway evaluation after 2
months, and personal visits if requested by staff mem-
bers, is offered to further facilitate implementation. The
COSMOS ambassador at each intervention NH will
supervise the overall delivery of the interventions, sup-
ported by four full-time COSMOS researchers (IA, CG,
TH and TE).
Effectiveness measures by core outcome measurements
Data collection for outcome measures will be completed
at baseline, months 4 and 9, conducted by the patient’s
primary caregiver who knows the patient, together with
a research assistant. Demographics will be collected
from the patients’ record. Selection of outcome mea-
sures is consistent with recommendations from the
Initiative on Methods, Measurement and Pain Assess-
ment in Clinical Trials (IMMPACT) [48].
Primary and secondary outcome measures
The primary outcome in the COSMOS trial is QoL as mea-
sured by quality of life in late-stage dementia (QUALID)
[49] and Quality of life in Dementia (QUALIDEM) [50]
(Table 1). We also use the European Quality of Life-5
Dimensions (EQ-5D) [51] in connection with Resource
Utilization in Dementia-Formal Care (RUD-FOCA) [44]
as one of the secondary outcomes. Other secondary
outcomes are Neuropsychiatric Inventory-Nursing Home
version (NPI-NH) [52], Cohen-Mansfield Agitation Inven-
tory (CMAI) [53], Cornell Scale for Depression in
Dementia (CSDD) [54], Mobilization-Observation-
Behaviour-Intensity-Dementia 2 (MOBID-2) Pain Scale
Table 1 Instruments used as primary and secondary outcome measures
What does the tool measure Tool characteristics & psychometric properties
QUALID*† [49] QoL by cognitive function, health, function,
social and psychological well-being.
11 behaviours rated on a 5-point Likert scale (range 11–55). Excellent
reliability, internal consistency and validity are reported. Lower score
indicates higher QoL
QUALIDEM*† [50] QoL by self-image, affect, restlessness, care and
social relation, feeling at home & active.
40 items scored 0–3 in 10 subscales yielding a sum score for each
subscale; care relationship (0–21), positive affect (0–18), negative affect
(0–9), restless tense behaviour (0–9), positive self-image (0–9), social
relations (0–18), feeling at home (0–12), having something to do (0–6),
undefined items (0–9). Sufficient reliability and validity are reported
EQ-5D*† [51, 69] QoL by mobility, self-care, activities, pain/
discomfort and anxiety/depression, and
impression of health
Patient or care-giver indicates patient`s state in f the 5 dimensions,
according to 3 levels: no, some or extreme problems, and total
impression of health (0–100). Scarce evidence for use in NH setting
& with/in people with dementia
NPI-NH*† [52, 70] Neuropsychiatric symptoms in dementia,
caregiver distress.
Total and subscale scores are provided based on frequency & severity
of symptoms (range 0–144). Good validity and reliability of the Norwegian
version of the NPI-NH. Including The neuropsychiatric inventory caregiver
distress scale
CMAI*† [53, X7] Agitation & behavioural disturbances 29 items (range 29–203). Good validity & reliability
CSDD*† [54] Depression in people with dementia 19 items rated from 0=no symptom to 2=severe. ≥8 = depression,
>12=moderate-severe depression. Satisfactory inter-rater reliability
and validity
MOBID-2 Pain
Scale*† [55]
Two-part pain location and intensity in
people with advanced dementia.
Pain intensity inferred by the patient’s pain behaviours during standardized,
guided movements (Part 1), and pain behaviours related to internal organs,
head and skin (Part 2). Excellent reliability, validity and good responsiveness
MMSE † [71] Differentiation of severity of cognitive
impairment
30-point scale where 0 to 11=severe impairment, 12 to 17=moderate,
18 to 23=mild, 24 to 30=no impairment
FAST*† [42, X14] Severity of dementia Stages dementia in 7 stages, 1 normal, 2 normal ageing, 3 possible dementia,
4 mild, 5 moderate, 6 and 7 severe dementia. Good reliability and validity
ADL*† [57] Physical function by rating activities;
feeding, moving, toilet and dressing.
The scale includes 6 items (range 0–30) Lower values indicates better
functioning and independence
CGIC* [72] Perceived improvement and efficacy 7-point rating ranging from very much worse (0) to very much improved (6).
Not intended as a sensitive measure of small changes, but for changes
considered clinically significant.
RUD-FOCA* [44] Cost-analysis of time use during 24 hours Total time per 24 hours is summed and mean time is calculated by
records of required care. Validated for use in NHs, acceptable test-retest
reliability and construct validity
* Proxy rated instrument, † Validated for use in people with dementia, ADL Physical Self-Maintenance Scale, FAST Functional Assessment Staging, CGIC Clinical
Global Impression of Change, CMAI Cohen-Mansfield Agitation Inventory, CSDD Cornell Scale for Depression in Dementia, EQ-5D European Quality of Life-5
Dimensions, MMSE Mini Mental State Examination, MOBID 2 Mobilization-Observation-Behaviour-Intensity-Dementia 2 Pain Scale, NPI-NH Neuropsychiatric
Inventory- NH version, QoL Quality of life, QUALID quality of life in late-stage dementia, QUALIDEM Quality of life in Dementia, RUD-FOCA Resource Utilization in
Dementia – Formal Care
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[55, 56], Personal Activities of Daily Living (P-ADL)
[57] and Clinical Global Impression of change (CGIC)
[58, 59]. We will use Actigraphy (Philips Actiwatch
Spectrum) to objectively assess sleep patterns and cir-
cadian rhythm and light exposure [60, 61]. Total medi-
cation and use of psychotropic drugs in number and
dose will be assessed with respect to drug-related prob-
lems and drug–drug interactions using STOPP and
START criteria [43] and anticholinergic list [43]. A full
description of the primary and secondary outcomes
and screening instruments MMSE [41] and FAST [42]
are provided in Table 1.
Indicators of effective implementation strategies
(qualitative)
The interventions will be observed and evaluated accord-
ing to i) perception among end users and stakeholders
that the intervention is “agreeable” (Acceptability); ii) staff
intentions and actions to employ the intervention (Adop-
tion); iii) perceived relevance of the intervention in NH
settings (Appropriateness); iv) degree to which the inter-
vention can be carried out in NHs (Feasibility); v) integrity
to and quality of intended program delivery (Fidelity); vi)
extent of institutionalization of the interventions, reach or
spread (Penetration); vii) maintenance and continuation of
the interventions; durability; integration; incorporation
(Sustainability) [62, 63]. The evaluations include analyses
of medical records and interviews of staff. Assessment of
the implementation of the COSMOS interventions will be
completed with monthly visits and phone calls to the con-
tact persons on each NH. The patient logs will help struc-
ture the phone conversations according to individual
intervention and patient. These semi-structured interviews
will be coded in accordance with the patient log. This en-
tails registering whether or not the planned interventions
have been carried out (yes/no/not applicable), and collect-
ing short statements regarding barriers and other relevant
comments.
Data management and analyses
A data manager will be responsible for punching, validating
and merging trial data. Data will be stored on approved
servers at the University of Bergen (UoB). Demographic
and clinical characteristics between intervention and con-
trol at baseline will be compared using Pearson χ2 test sta-
tistics for categorical variables and independent samples t
test for normal variables (age, diagnoses and pain diagno-
ses). Analysis of covariance (ANCOVA) estimates the mean
effect in each trial arm, weighted across clusters (1 cluster =
1 NH unit) according to number of patients within each
cluster, and from this, the mean treatment effect is esti-
mated at each time point [47]. The intraclass correlation
coefficient (ICC) expresses the proportion of the total vari-
ance in data between included clusters. Primary efficacy
population includes all patients with at least one post-
baseline assessment (month 4 measure), and we will use a
linear intercept mixed model in a two-way repeated mea-
sures configuration to assess change over time. Treatment
effect will be expressed as estimated effect of intervention,
along with a 95 % confidence interval and p values ≤0.05
for each time point. The Mann-Whitney U test will be
used for non-normal distributed continuous variables such
as QUALID [49], QUALIDEM [50], NPI-NH [52], CMAI
[53], CSDD [54], MMSE [41], MOBID-2 Pain Scale [55],
CGIC [59] and P-ADL [57]. Cost-utility analysis will be
performed including costs for pharmaceuticals, resource
use in NHs and use of external heath care facilities [44]. A
full statistical analysis plan, including potential missing
data imputation for each outcome measure, will be devel-
oped through the course of the study.
Sample size analyses
QoL is our primary outcome measure, and ongoing
comparable intervention studies conduct similar sam-
ple size analyses; however, we are not aware of large-
scale studies presenting the effect of a multicompo-
nent intervention on QoL outcome measures such as
QUALIDEM or DEMQOL. Based upon the magnitude
of improvement in our previous RCT on pharma-
cological interventions [15] for neuropsychiatric
symptoms in NH patients, we estimated that a 25 %
reduction of the NPI-NH scale (SD 5 standardized
effect size [SES] 0.4) for comparison of the interven-
tion and control group at month 4. To measure a dif-
ference of this magnitude requires a minimum of 81
patients allocated to each arm of the trial, for a sig-
nificance level of 5 % (two sided), a power of 80 %
and equal allocation. As cluster designs lead to loss
of power [47], the sample size should be multiplied
by 1 + (m − 1)ρ, called the design effect, where m is
the average cluster size and ρ = s2b/(s2b + s2w) is the
ICC, where s2b is the variance between clusters, and
s2w is the variance within clusters. Based on add-
itional assumption of an estimated ICC of 0.157 in the
earlier trial with an intervention over 8 weeks [15], an
average of 10 eligible patients in each cluster gives a
DE = [(1 + (11 − 1) × 0.157)] = 2.57 [15]. Thus, we need a
minimum of 208 (2.57 × 81) patients per arm, or 416
patients in total. We expect a drop-out rate between 20 to
25 % [64] from baseline to month 4. Thus, we need a re-
cruitment of an additional 104 participants (520 in total),
with 32 clusters (NH units) in each arm. COSMOS will be
conducted in at least 64 NH units (clusters), with an
average of 8–12 patients on each unit.
Ethical approval
The trial is approved by the Regional Committee for Med-
ical and Health Research Ethics, West Norway (REK 2013/
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1765), and registered at clinicaltrials.gov (NCT02238652).
Verbal and written informed consent was obtained in
direct conversations with all cognitively intact patients
with sufficient ability to consent. In patients lacking the
ability to consent, verbal and written informed and pre-
sumed consent was obtained in direct conversation with
the patient (if possible) and his or her legal guardian,
usually a family member or advocate, after explaining the
aims and protocol of the study.
Trial status
The trial is an ongoing project; we have completed the
pilot, included participants in the trial and now com-
menced implementation of the COSMOS intervention
and data collection at baseline and follow-up, at the time
of manuscript submission.
Discussion
COSMOS intends to improve the QoL in NH patients
by enhanced communication and ACP, systematic as-
sessment and treatment of pain, medication review and
organization of meaningful activities provided by edu-
cated NH staff. Thereby, the intervention aims to im-
prove the mental and physical health of the people,
safety and cost-effectiveness and reduce unnecessary
medication and hospital admission.
The development of the multicomponent approach is
built on evidence-based research results of single-
intervention studies. In fact, this intervention was in-
spired by prompt feedback from NH staff in response to
our pain research: “of course, it is important that NH
patients are pain free, but our problem is not primarily
the pain, but rather the communication—we do not talk
to them, early enough” or “nice with less medication,
but our problem is lack of activities”. Our research team
realized that complex health challenges in NHs are in
need of complex and multifaceted and systematic
interventions.
In the absence of a comparable study design, the
length of a 4-month period is based on current results
by a trajectory study demonstrating a death rate of 29 %
during the first year after NH admission (submitted).
Based on the 2-month pilot study, we recognized that
the NH staff needs enough time to get familiar with the
COSMOS intervention, teach new colleagues and make
necessary changes in the unit. On the other hand, the
study period should not be too long, to avoid patient
drop-out and ensure staff compliance.
This study design has its limitations. We are aware
that the combined COSMOS components into a com-
plex intervention investigated with a cluster randomized
research design make the trial more impractical and ob-
jectionable compared to a single intervention [65]. It has
previously been described that the complexity resulting
from interactions among many component parts de-
creases the predictability of effects [66]. Despite this
limitation, we argue that the combination of several
components to a multifaceted intervention is necessary
to cover a larger area of unmet needs in NH patients
and people with dementia. In addition, we suggest that
the concept may mimic the clinical reality. To deal with
this methodological challenge, we followed recommen-
dations by the implementation science for development
and testing of multicomponent healthcare interventions
[67]. It has previously been highlighted that the develop-
ment, implementation and evaluation of any new and
systematic healthcare intervention are complex proce-
dures [60]. To avoid study complexity and unpredictabil-
ity, researchers usually reduce study designs to one of
the most essential parts in order to fulfill strict RCT re-
quirements [67]. This reduction may result in a complex
intervention being reduced to a series of simple inter-
ventions; doing so fails to acknowledge that a complex
intervention has the potential to be more than the sum
of its parts. Optimistically, results of this study will dem-
onstrate the efficacy of this intervention and satisfaction
in patients, staff and relatives. In addition, we expect to
contribute to further development of implementation re-
search in the NH setting.
It is also widely recognized [47] that RCTs are less ef-
ficient, in a statistical sense; compounded by the effect
of personal interactions among cluster members who
receive the same intervention. For example, education
strategies provided during teaching lessons could lead
to sharing of information that creates a cluster effect.
Circumstances have an impact on sample size analyses
and the necessary volume of the study. Attempts to
minimize contamination were made (e.g. geographical
distance between NH units and same physicians do not
serve different units of control and intervention
groups). In addition, we have included a larger group of
patients and clusters in accordance with the sample
size analysis adjusted for the ICC effect. Until now,
there are few comparable studies: The WHELD study
[68] includes even more participants; however, the
intervention method uses a grid design with different
intervention approaches resulting in increased sample
size.
Taken together, several structural factors may influ-
ence the implementation process and outcome measures
[38]. Although much is known about the effectiveness of
interventions that benefit aspects of physical and mental
health, any intervention is of limited value unless it is
practical and can be implemented routinely in clinical
practice [37]. Research is imperative to understand and
evaluate potential obstacles to refine interventions and
competence improving programs through extensive field
testing.
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Table 2 2-day education program for COSMOS ambassadors,
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Themes
Day 1
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nursing homes (NH)
09:00 The multicomponent concept of COSMOS, introduction
and plan for teaching, education and follow-up of patients,
relatives, NH staff including managers
09:45 Module 1: Assessment and treatment of pain
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stepwise protocol of treatment pain
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10:45 Efficacy of treating pain on neuropsychiatric symptoms in
people with dementia
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Day 2
08:30 Welcome and coffee
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Polypharmacy in elderly people and NH patients with and
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www.interaksjoner.no
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Table 2 2-day education program for COSMOS ambassadors,
physicians and nursing home managers (Continued)
15:30 Practical exercises in identification of promoters and
barriers to conduct ACP in my NH; introduction of the
manual and demonstration material for the cluster/NH unit
16.15 What are the next steps? Contact with patients and
relatives, telephone hotline, information posters/pocket
cards, flyers, contact with media, web-site and more.
16:30 Program evaluation
17:00 Take home message
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